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bstract
Breast cancer is the second leading cause of death from cancer in women in the United States. A growing emphasis is being placed on alternative
edicine and dietary approaches toward prevention of potential diseases. Phytochemicals are bioactive compounds that are naturally present in
oods that, when acting in synergy, bestow potential anti-cancer properties. Resveratrol, a phytoalexin, and ursolic acid, a pentacyclic triterpenoid,
re two bioactive compounds that are at the forefront in scientific research. Previous animal studies have documented the anti-cancer properties
f resveratrol on breast cancer cells and research groups have recently been able to identify the anti-cancer, anti-inflammatory and induction of
poptosis properties of resveratrol along with the signal transduction pathways that the compound affects. Ursolic acid has been cast into the
imelight with the recent discovery documenting its anti-inflammation and anti-cancer activities by targeting signal pathways, especially in the
revention of breast cancer.
 2012 Production and hosting by Elsevier B.V. on behalf of Beijing Academy of Food Sciences.
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.  Introduction
Cancer along with cardiovascular disease (CVD) are two of
he leading causes of death in the United States; the preva-
ence of which is also seen at higher rates in developed and
ndustrialized countries. According to the 2010 Cancer Statis-
ics [1], an estimated 1.5 million individuals will be diagnosed
ith different forms of cancer. The most prevalent form of can-
er in men is that of the prostate, accounting for 28% of the
otal cases diagnosed, with lung cancer being the second most
robably at 15%. In the cases of women, breast cancer is the
eading cause accounting for 28% of the total individuals diag-
osed, with lung cancer being the second most probably at 14%.
∗ Corresponding author at: Department of Food Science, Stocking Hall, Cor-
ell University, Ithaca, NY 14853-7201, USA. Tel.: +1 607 255 6235;
ax: +1 607 254 4868.
E-mail address: RL23@cornell.edu (R.H. Liu).
eer review under responsibility of Beijing Academy of Food Sciences.
213-4530 © 2012 Production and hosting by Elsevier B.V. on behalf of
eijing Academy of Food Sciences.
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Traditional cancer treatments including chemotherapy, radiation
herapy, surgery, immunotherapy and biologic therapy are reg-
larly used in treating cancer at various stages. Though they
ffer an effective way to reduce cancer, the patient often suffers
rom numerous side-effects. This has led to the emergence of
lternate forms of cancer treatment such as nutrition therapy,
hich serves to fight cancer through a healthy diet while pre-
enting none of the side-effects often encountered by patients
ndergoing treatment.
Strong associations between high dietary intakes of fruits,
egetables and whole grains, with a reduced risk in chronic
isease development have consistently been reported in numer-
us epidemiological studies [2–4]. It has been estimated that
/3 of all cancer related deaths in the United States can
e avoided through appropriate dietary modification; this co-
elation between diet and health suggests a change in dietary
ehavior, through an increase in consumption of fruits, vegeta-
les and whole grains, along with related lifestyle, as a potential
trategy for significantly reducing the incidence of cancer.
The cells present in human body as well as in other organisms
re often exposed to a varying variety of oxidizing agents, a
ew of which are necessary for life. These oxidizing agents can
e present in the air, food, as well as water, or they can even
e produced as a result of metabolic activities within the cells.
he importance lies in the careful balance between oxidants and
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nti-oxidants ensuring the sustenance of an optimal physiolog-
cal condition. In situations where oxidants are overproduced,
he imbalance induced as a result of oxidative stress, especially
n chronic bacterial, viral as well as parasitic infections [5]. The
nset of oxidative stress results in oxidative damage to large
iomolecules such as lipids, proteins and DNA leading to an
ncrease in the risk of cancer [5–7].
The formation of cancer is a multi-stage process with the
amage induced by oxidation linked to the formation of tumors
hrough different mechanisms [5,6]. Free radical induced oxida-
ive stress can result in significant DNA damage. Unless proper
epair mechanisms are initiated, this damage can cause base-
utation, single as well as double strand breakages, DNA cross
inking as well as chromosomal breakage and rearrangement [6].
.1. Dietary  approach  to  cancer  treatment
This potentially cancer-inducing oxidative damage might be
revented or limited by dietary antioxidants in fruits and veg-
tables. The anti-oxidant activities of fruits and vegetables are a
onsequence of the present phytochemicals.
Phytochemicals are defined as bioactive non-nutrient com-
ounds in fruits, vegetables, whole grains and other plant foods
hat have been linked to reducing the risk of major chronic dis-
ases [8]. More than 5000 phytochemicals have been identified
n fruits, vegetables and grains. They are generally classified
nto carotenoids, alkaloids, phenolics, nitrogen containing com-
ounds and organosulfur compounds. Phytochemicals obtained
hrough the diets have the capability to prevent cancer or inter-
ere with cancer progression at various stages of its development.
resent studies also indicate the ability of phytochemicals to
xpress anti-oxidant activity as a result of their free radical
cavenging property; to regulate gene expression in cell prolifer-
tion, cell differentiation, oncogenes as well as tumor suppressor
enes; to induce cell cycle arrest and apoptosis; to modulate
nzyme activities in detoxification, oxidation and reduction;
o stimulate the immune system; and to regulate hormone-
ependent carcinogenesis and have anti-bacterial and anti-viral
ffects [9–15].
Amongst the many phytochemicals present, the compounds
ith greatest importance include resveratrol and ursolic acid.
ver since the inverse relationship between the consumption
f wine and cardiovascular disease was established [16–18],
he underlying phytochemicals that may be responsible have
eceived a lot of focus in the scientific domain attributing to
ts numerous health benefits. With the discovery of resveratrol
n red wine [19] numerous researches have been conducted for
ocumenting its anti-cancer, anti-aging, anti-inflammatory and
 plethora of other beneficial properties. The compound has been
sed to conduct a lot of potential research to further gauge its
apabilities. Ursolic acid is a phytochemical present in numerous
erbs, fruits and vegetables, and has often been associated with
erbal medicine. Though research data on the potential benefits
f the compound was initially scarce owing to the lack of oral
ioavailability data, with detection of ursolic acid in cranberries,
pples and other fruits along with anti-cancer properties, the
ompound has generated renewed interest in scientific research
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xploring its potentials. Recently with the discovery of urso-
ic acid to reduce obesity and burn calories, the compound is
urrently in the spotlight in terms of its potential health benefits.
This review will focus on the anti-cancer properties of the two
hytochemicals through an analysis of various epidemiological,
nimal model and clinical trial studies with a focus on breast
ancer.
. Resveratrol
Resveratrol was first isolated in 1940 from hellebore roots
20,21]. Research into the potential health benefits of the com-
ound was carried out shortly after the discovery of resveratrol
roduction in grape vines when they were infected by fungus
21]. Following the discovery of resveratrol in wine [19] the
ompound was hypothesized as the primary underlying factor
esponsible for the “French Paradox”, a term coined by Dr. Serge
enaud [22]. The paradox serves to describe the decrease in
ncidences of cardiovascular disease amongst the French pop-
lation that consume a diet which is much higher in saturated
at compared to an American diet. One of the hypotheses was
roposed due to the regular consumption of wine along with the
raditional diet [18,19,22]. On the basis of this link to a potential
ealth benefit, scientists then began to fully explore the potential
ardiovascular benefits associated with resveratrol. Shortly after,
esveratrol was revealed to inhibit tumor initiation, promotion
s well as progression for cancer prevention [23].
A number of scientific studies report a plethora of appli-
ations of resveratrol pertaining to anti-aging activity [24,25],
nti-cancer properties [26,27], cardio-protective effects [28,29],
nti-diabetic properties [30,31], as well as anti-inflammatory
32,33], anti-viral [34,35] and neuro-protective effects [36,37].
.1. Structure  and  chemistry
Resveratrol is a phytoalexin produced by plants as a result of
acterial and fungal attack. It is a defense mechanism adopted
y plants suited for their survival against pathogen attack. Phy-
oalexins are toxic compounds synthesized de-novo by plants
esigned to delay cell maturation, prevent reproduction of the
athogen and puncture pathogen cell walls.
Resveratrol is a stilbenoid, a derivative of stilbene and is
roduced with the assistance of the enzyme stilbene synthase.
he chemical name for resveratrol is usually given as 3,5,4′-
rihydroxystilbene. Stilbenes are a form of phyto-estrogens
onsisting of trans-ethane double bond substituted with a
henyl group on both the double the carbon atoms of the
ouble bonds. They are mainly constituents of the heartwood
f the widely known eucalyptus genera, along with Pinu
nd Malcura. Stilbenes consist of two aromatic rings joined
y a C2 bridge and generally exist in two forms; the trans-
tilbene and the cis-stilbene. As with all stilbenes, resveratrol
xists in a cis- and trans- form with the trans-resveratrol
nown to be ideally more stable [38]. The inter-conversion of
rans-resveratrol to its cis-form can be seen upon exposure to
ltraviolet radiation [39]. Resveratrol also has three different
nalogs: (E)-5-(2-(Quinolin-4-yl) vinyl) benzene-1,3-diol,
nce an
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E)-4-(3,5-dimethoxystyryl) quinoline and (E)-4-(3,5-
imethoxystyryl) phenol [40], which are similar in structures to
esveratrol and possess anti-oxidant activity [41].
.2. Sources
Resveratrol has been identified in more than 72 plant species
ncluding red grapes, peanuts and mulberries, which are com-
on in the human diet [23,42,43]. The resveratrol content varies
rom different food sources with peanuts being found to have
pproximately half the amount of resveratrol as compared to
he amount in wines. While considering blueberries, they were
ound to have twice the amount of resveratrol compared to
ilberries with a pattern of regional variation being observed.
ince resveratrol is not heat stable, cooking or any form of ther-
al processing involving these fruits will subsequently degrade
he resveratrol present in them. It should be noted that in the
ase of grapes, the amount of resveratrol varies with respect to
he grape cultivar, geographic origin and probable exposure to
ungal infection [39,44].
.3.  Bioavailability  and  intra-cellular  absorption  and
etabolism
One of the main reasons for a low cellular concentration of
esveratrol, even though approximately 70% of it administered
rally are absorbed, is due to its rapid breakdown into the conju-
ated metabolites: glucuronate and sulfonate [45], amongwhich
he pre-dominant forms are trans-resveratrol-3-O-glucuronide
nd trans-resveratrol-3-sulfate. The glycosylated form of resver-
trol, being more stable and resistant to oxidative degradation,
s absorbed in the human gastro-intestinal tract [46]. Unchanged
r free resveratrol in negligible concentrations below 5 ng/mL
fter an oral dose of 25 mg [45], is lower than the concentration
f 5 mol which is required to elicit a pharmacologic activity
47–49]. Needless to say, it has been seen that a high dosage of
esveratrol has cytotoxic properties toward breast cancer cells
wing to structural similarity to phytoestrogen [50,51] as well
s resveratrol’s ability to slow down the potential development
f blood vessels, which may result in a delay of healing [52].
hey have been shown to display antioxidant, anti-mutagenic
s well as anti-initiation, promotion and progression activities
23].
Taking the proposed beneficial health properties displayed by
he bioactive compound in conjunction with it being a regular
onstituent in the human diet, resveratrol is an important phyto-
hemical in its contribution toward breast cancer prevention.
.4. Inhibition  of  cell  proliferation  and  apoptosis
Resveratrol has been shown to inhibit cancer cell proliferation
hrough the subsequent down-regulation of numerous prolifera-
ive and anti-apoptosis gene products [53]. The anti-proliferative
ctivity of resveratrol has recently been documented in MCF-7
reast cancer cells, where the treatment caused a dose-dependent
nhibition of cell growth along with an accumulation of cells in
he S phase of the cell cycle at lower resveratrol concentrations
m
e
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54]. The inhibition of cell growth is attributed to the ability
f resveratrol to initiate apoptosis as evidenced by the presence
f condensed chromatin as well as the detection of a sub-G1
raction. Treating synthetic resveratrol on ER+ and ER- breast
ancer cell lines show a similar anti-proliferative and apoptotic
ctivity [55]. Three cell lines were used in this study, KPL-1 and
CF-7, both of which were ER+ and MKL-F which is ER−.
ow concentrations of resveratrol induce cell proliferation in
he ER+ cell lines at concentrations of <4 mol/L in the case
f MCF-7 and <22 mol/L for KPL-1. At higher concentrations
>44 mol/L), all three cell lines displayed a reduction in cancer
ell growth, which is attributed to the induction of apoptosis as
videnced by the presence of sub-G1 fractions.
Despite the potential of resveratrol as an anti-oxidant and
n anti-cancer agent, it is present at a small concentration in red
ine compared to the other phenolic compounds present such as
atechin, epicatechin and quercetin, which together account for
ore than 70% of the total phenolic content [56], and micromo-
ar level concentrations are required to produce any significant
enefit [56]. When the anti-proliferative activity of red wine was
ested on hormone resistant and hormone sensitive breast can-
er cell lines, phenolic concentrations at the picomolar and the
anomolar range were found to decrease cancer cell prolifer-
tion at a time- and dose-dependent manner [57]. They were
ble to observe a specific interaction between individual phe-
olic compounds and their respective steroid receptors in the
ase of hormone sensitive breast cancer cell lines, MCF-7 and
47D. Distinct anti-oxidant activities were also seen in the tested
ell lines at similar concentrations. Bowers [51] reported that
esveratrol exhibited agonist/antagonist activity toward alpha-
nd betastrogen receptors. In light of that observation, the effect
f resveratrol treatment, in combination with estradiol, on the
ell growth of ER positive breast cancer cell line, MCF-7, and ER
egative cell line, MDA-MB-468, was studied [58]. Resveratrol
t a concentration of 10 mol/L, inhibited 1 nmol/L estradiol
editated cell growth along with an alteration in the expres-
ion of autocrine growth modulators and receptors in the MCF-7
reast cancer cell line. Resveratrol also inhibited cell prolifera-
ion in the ER negative breast cancer cell line, MDA-MB-468.
hese findings substantiated the estrogen receptor antagonist
ctivity of resveratrol and proposed an alternative mechanism for
nhibiting cell proliferation through the alteration of autocrine
rowth modulators and receptors.
The efficacy of resveratrol as a potential anti-proliferative
gent for both hormone resistant and hormone sensitive, breast
ancer cell lines was substantiated in a study where synthetic
esveratrol at concentrations of 5, 10, 20 or 40 g/mL were
reated with MCF-7, MCF-10F and MDA-MB-231 breast can-
er cells [59]. The treatment period ranged from 24 h to 144 h
nd a time- and dose-dependent inhibition of proliferation for
ll three cell lines were observed along with a decrease in the
umber of viable cells, which suggested resveratrol inhibited
ell proliferation thorough the estrogen receptor independent
echanism.
Depending on the concentration, resveratrol exhibited
strogenic/anti-estrogenic effect on the ER positive and ER
egative breast cancer cells and was associated with growth
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nhibition through different targets in the proliferative and apop-
otic pathways [60]. A recent study aimed at investigating the
iological properties of a boronic acid derivative of resveratrol
n ER positive MCF-7 breast cancer cells [61]. The trans-4
nalog was seen to induce the cell cycle G1 arrest and as such
isplayed no obvious effect on the estrogen stimulated MCF-7
ells.
.5. In  vivo  studies
The properties of resveratrol in the prevention of breast can-
er was observed in a N-methyl-N-nitrosourea (NMU) induced
ammary tumors in Sprague–Dawley rats [60] since the under-
ying cause or origination of cancer in this model is relevant
o human breast cancer [62]. Resveratrol treatment reduced the
nset of tumor multiplicity as well as increasing the latency
eriod by 27 days. The tumor formation in the treated rats
educed by 50% over a period of 69 days, following which the
ncidence continued to increase to reach that of the control.
A recent animal study showed resveratrol’s ability to pre-
ent the shedding of tumor cells from mouse mammary cancer
pheroids and to inhibit cancer cell invasion [63]. The tumor
rowth was found to be inhibited through a phenol mediated
xpression of the proliferation marker Ki-67 and the phenol
ediated down-regulation of MMP-9, and ROS generation
as responsible for the prevention of tumor cell shedding. In
ontrast, when pre-pubertal female rats were treated with resver-
trol, it resulted in endocrine system disruption along with
n accelerated development of MNU-induced mammary carci-
oma in Sprague–Dawley rats [64]. Another study showed that
igh doses of trans-resveratrol administered to Sprague–Dawley
ats for a period of 28 days at a dose of 20 mg/kg/day was found to
e harmless [65]. The post treatment analysis indicated no neg-
tive effect on growth as well as normalcy to most vital organs.
he mean growth rate, final body weight and the lipoprotein
rofiles were all seento be not affected by the high dose treat-
ent with resveratrol. When pharmacologic levels of resveratrol
ere used to treat ER−  and ER+ MDA-MB-231 tumor cells
n nude mice, a decrease in angiogenesis, tumor growth and
poptotic index was observed when compared to the control
66]. A significantly reduced extracellular vascular endothelial
rowth factor (VEGF), a protein that stimulates vasculogene-
is and angiogenesis, was also seen. Resveratrol is known to
nhibit angiogenesis by the suppression of VEGF action through
 reduction in the MAP kinase phosphorylation thereby leading
o a block in the VEGF receptor mediated response [52]. This
uggests a possible mechanism exhibited by resveratrol in affect-
ng angiogenesis through VEGF secretion as well as influencing
he downstream cell signaling pathways of the VEGF receptor
66].
.6. Molecular  targets  and  signal  pathway  studiesResveratrol has been shown to inhibit the invasive and migra-
ion properties of MDA-MB 435 breast cancer cells through
he inhibition of insulin-like growth factor-1 (IGF-1), a stimu-
ant for breast cancer cell migration [67]. IGF-1 induces cancer
b
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ell migration in the estrogen receptor negative (ER-negative)
reast cancer cells through the activation of the PI-3K cellu-
ar signaling pathway. Resveratrol was found to suppress cell
igration through the inhibition of the PI-3K/AKT pathway in
 dose dependent manner. IGF-1 also up-regulated the Matrix
etalloproteinase (MMP) activity in cancer cells, which was
esponsible for their invasive and metastasis properties [68].
ased on the research findings, resveratrol was revealed to mod-
late the MMP-2 levels in a dose-dependent manner through
he post-translational regulation of protein synthesis. HRG-1
growth factor) mediated MMP-9 expression was also seen to
e inhibited by resveratrol along with the suppression of ERK
/2 phosphorylation [69]. This indicates the inhibitory effect of
esveratrol on breast cancer cell invasion and MMP-9 expres-
ion being attributed to the down-regulation of the MAPK/ERK
ignaling pathway. Following the findings of a dose-dependent
nhibition of the PI3K pathway, a study was conducted to observe
he downstream signaling of PI3K in order to understand the
echanism of resveratrol-induced apoptosis. Bcl-2 was found
o be down-regulated along with the inhibition of necrosis factor
appa-beta (NF-к), a regulator of Bcl-2 expression, and cal-
ain protease activity. These findings were in conjunction to a
ecrease in mitochondrial membrane potential and an increase
n nitric oxide production and reactive oxygen species (ROS).
ased on these findings, Bcl-2 and NF-к  were considered to be
otential targets for the anti-cancer activity of resveratrol [70].
Resveratrol has been found to bind with Integrin V3, a
etero-dimer, at the receptor which is close to the Arg-Gly-Asp
RGD) recognition site on the Integrin which is required for
he transduction of the stilbene signal to a p53 dependent apo-
tosis of breast cancer cells [71]. Taking it into consideration in
ccordance with the limited bioavailability of resveratrol, a com-
arative study on signaling pathways elicited by resveratrol and
ts derivatives was carried out. The findings suggested that on
inding of resveratrol and trans-resveratrol to integrin V3 the
38 kinase pathways were activated, subsequently followed by
he activation of p53; but in the case of trimethoxy-resveratrol,
inding to integrin V3 activated a different MAPK pathway
eading to the activation of p53 and the induction of apoptosis
72]. This serves to suggest the different convergent and diver-
ent signaling pathway as well as numerous mechanisms prior
o the binding with integrin V3 and the subsequent activation
f p53. Cyclooxygenase-2 (COX-2) is an enzyme that is mea-
ured at high levels during inflammation; it is an anti-apoptotic.
reatment of breast cancer cells with resveratrol has been found
o increase the nuclear accumulation of COX-2 where they inter-
ct with p53 and p300, a co-activator of p53 gene expression,
nd form a complex resulting in the facilitation of apoptosis
n resveratrol treated MCF-7 and MDA-MB-231 breast cancer
ells [73]. This finding served to distinguish between the cancer
romoting properties of constitutive COX-2 expression and the
roapoptic properties of inducible COX-2 expression that sup-
orts resveratrol induced p53 expression. Breast cancer 1 and
reast cancer 2 (BRCA 1 and BRCA 2) are genes that produce
roteins responsible for DNA repair. The mRNA expression of
reast cancer susceptibility genes, BRCA 1 and BRCA 2, was
ound to be increased following resveratrol treatment. Following
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he treatment of MCF7, MDA-MB 231 and HBL 100 breast can-
er cell lines with 10, 30 and 50 M trans-resveratrol at varying
xposure times, a blockage of cancer cells in the S phase in the
hree cancer cell lines was observed along with an increase in S
hase cells and a decrease in cells in the G1 phase. The mRNA
xpression of the BRCA 1 was found to be increased with no
hange being detected in the case of the BRCA 2 genes [74].
A limitation encountered while weighing the benefits associ-
ted with administering resveratrol is the limited bioavailability.
rans-Resveratrol is metabolized in the body, particularly in
he intestine and the liver, and is stored as glucuronide and
ulfate conjugates. The uptake and metabolism of resveratrol
as recently studied in ZR-75-1 and MDA-MB-231 breast
ancer cell lines where they were able to observe the exten-
ive formation of resveratrol-3-O-sulfate in the ZR-75-1 cells
ompared to the MDA-MB-231 cell line [75]. Contrary to tra-
itional metabolism, resveratrol glucuronide was not detected
n either cell lines. They were able to identify a significant
o-relation between SULT1A1 (sulfotransfrase) expression and
esveratrol-3-O-sulfate formation in ZR-75-1 cells while a
ow co-relation was seen in the case of MBA-MB-231 cell
ine. The increase in the resveratrol-sulfate metabolite resulted
n the excretion of the product from the cells which subse-
uently caused the lowering of the intra-cellular resveratrol
oncentrations as an offset [75]. This explains the lower anti-
ancer activity of resveratrol on the ZR-75-1 breast cancer cell
ine. Resveratrol is passively absorbed into the cells where
hey are metabolized into respective glucuronide and sulfate
etabolites. The efflux of the resveratrol metabolism prod-
cts occuredthrough the ABC transporters, multi-drug resistance
ssociated protein (MRP2) and breast cancer resistance protein
BCRP) [76]. The functional importance of BRCP was fur-
her established in a study where wild type and Brcp−/−  mice
here orally administered 60 mg/kg of resveratrol followed
y a trans-resveratrol and metabolite concentration analysis
n the intestine, plasma and tissues. A considerate reduction
n metabolite efflux was observed in the knockout variant
ith an inhibition of 70% and 95% for glucuronide conju-
ate and sulfate conjugate respectively, which indicated at a
ubstrate specificity of the sulfate conjugate to brcp1 [77].
he formation of resveratrol-3-O-sulfate was considered to be
ose-dependent on resveratrol concentration. At higher con-
entrations of resveratrol, the formation of sulfate decreased
s a result of non-competitive substrate inhibition [78]. When
esveratrol-3-O-sulfate metabolite was leveled where compared
etween malignant and non-malignant breast cells, the sulfate
onjugate was found at a greater extent in the tumor tissue owing
o the over-expression of steroid sulfatase (STS) in the control
78].
An in  vitro  and in  vivo  study on the metabolism of resveratrol
n human, rat and mouse models showed trans-resveratrol-
-O-glucouronide and trans-resveratrol-3-sulfate as the most
bundant metabolites of resveratrol [79]. The in  vitro  experi-
ents involved the incubation of resveratrol with human liver
hromosomes, human hepatocytes and rat hepatocytes while
he in  vivo  studies involved oral administration of resveratrol
o rats and mice. From the studies of human microsomes and
t
a
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epatocytes, intact resveratrol but no metabolites were detected
n human liver microsomes. Abundant resveratrol metabolites
ike trans-resveratrol-3-O-glucuronide and tans-resveratrol-3-
ulfate were observed in rat urine, mouse serum and the rat
nd human hepatocytes incubations. In order to confirm the
tructures of the conjugates, incubation with glucuronidase and
ulfatase was performed to release free resveratrol. They were
nly able to observe trace amounts of cis-resveratrol indicat-
ng that isomerization did not play a significant role in the
etabolism of resveratrol.
In order to address the limitations associated with bioavail-
bility, a solid nanoparticle (SLN) mediated uptake of resveratrol
RSV) was studied by Teskac and Kristl [80]. This study was
one to explore the potential for colloidal carriers in delivering
hemo preventive drug resveratrol to specific, desired locations.
he effects of the SLN-RSV complex on factors such as growth,
orphology, metabolic activity and genetic material of keratino-
ytes were observed compared to that of RSV alone in solution.
he results showed that approximately 15% of RSV was not
ound to SLN, with a slow and sustained release of RSV after
5 min indicating a peripheral location of RSV. Additional col-
oidal structures in SLN such as micelles, mixed micelles and
iposome provided additional spaces for RSV. The cells were
ound to rapidly cross the membrane and a significant amount
f the administered dose was taken up by the cells. The internal-
zed SLV did not stay in one place and was in constant motion
n the cytosol with the cells remaining completely viable. SLN-
SV at a concentration of 10 m led to no change in the cell
orphology but at a concentration of 100 m, the cells were
lightly enlarged and their number reduced when compared to
SV alone in solution. An increase in metabolic activity by
0% relative to the control was observed on treating cells with
LN-RSV and SLN alone did not influence the metabolic activ-
ty. On incubation of cells with SLN-RSV, cells moved from
he G1 phase to the S phase, followed by a significant decrease
n G2/M phase. An increased metabolic activity was seen in
he case of SLN-RSV indicating intracellular transport of SLN
ncreases RSV efficacy. A sparse confluence was observed after
ncubation of cells with RSV or SLN-RSV alone. The overall
ytotoxicity associated with RSV was avoided by its delivery
ith SLN. The research data indicated the cytostatic effectives
f the SLN-RSV complex compared to RSV alone in solution.
Treating cancer cells with resveratrol has been shown to result
n a plethora of metabolic changes. In a recent analytical study
n the metabolic effect induced by resveratrol on MCF-7 and
DA-MB-231 cancer cells, treatment was found to increase
he synthesis of 21 amino acids 100 fold at a concentration of
00 mol, to modulate the bio-synthesis of polyamine, and to
timulate the putrescine and spermidine synthesis, to increase
xtracellular arachidonic acid, to reduce prostaglandin E2 lev-
ls (PGE2), as well as to increase in expression of tryptophan,
erotonin and kynurenine [81].
An analysis on the pharmacokinetics of resveratrol showed
hat (BRCP and MRP 3) played a vital role [82]. Both BRCP
s well as MRP 3 play an important role in the transport of
esveratrol and its metabolites: resveratrol sulfate and resver-
trol glucuronide. BRCP has a lower affinity to resveratrol
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lucuronide compared to MRP 3 and as such the two proteins
re responsible for the disposition of resveratrol in the cells [82].
 lack of MRP proteins reduces the amount of resveratrol that
s secreted though the urine whereas a lack of BRCP protein
esults in the formation of resveratrol di-sulfate along with an
ncrease in resveratrol secretion through the urine.
Resveratrol suppresses the synthesis of PGE2 through the
nhibition of COX-2 enzyme activity [83]. Upon phorbol ester
ediated (PMA) induction of COX-2, an increase in PGE2
roduction was seen. They were able to observed that resver-
trol caused a dose-dependent suppression of PGE2 synthesis
n human mammary cells and when compared to a selective
nhibitor of COX-2, the synthesis decreased by 10% to control
evel indicating that more than 90% of the remaining activity in
he mammary epithelial cells was due to the COX-2 isoforms.
esveratrol suppressed the higher rates of synthesis along with a
arked decrease in c-jun expression; PMA-mediated induction
f c-myc transcription was not inhibited. A 6 fold increase in
OX-2 activity following treatment with PMA was seen with
esveratrol inhibiting this induction. PMA and resveratrol were
ediated via  a cyclic AMP response. Resveratrol was also found
o inhibit PMA-mediated activation of protein kinase C along
ith the over expression of Cjun, ERK1 and protein kinase c-
lpha, all of which increased the COX-2 promoter activity [83].
esveratrol also blocked the AP-1 mediated gene expression
ctivation through the PKC signaling cascade [83].
Recently an analog of resveratrol, cis-3,4′,5-trimethoxy-
′
-hydroxystilbene, has been shown to display anti-cancer
roperties at concentrations lower than that of resveratrol
84]. The proposed compound functions by disrupting the
olymerization of microtubules. The reported potency of the
ydroxyl-stilbene analog over resveratrol was due to the ability
f the analog’s hydroxyl group to form hydrogen bonds with Val-
181 of tubulin. The cis-3,4′,5-trimethoxy-3′-hydroxystilbene
nalog was shown to accumulate the MDA-MB-231 breast can-
er cells in the G2/M phase, which was in conjunction with
eported data showing long term accumulation of cells in the M
hase results in apoptotic cell death known to be mediated by
aspase-3, PARP and Bax.
Resveratrol arrested cell proliferation, induced cell death, and
ecreased the number of cell colonies that were sensitive to
aspase-3-dependent apoptosis [85]. The activation of Beclin-1
ependent autophagy in the two cell lines by resveratrol was
esponsible for triggering cell death but the functionality was
locked by the expression of capase-3. This serves to indicate
he potential process through which resveratrol initiates capase-
ndependent cell death.
Resveratrol is known to act as an ER agonist and an aryl
ydrocarbon receptor (AHR) antagonist with previous studies
ndicating that the expression of ER limits the compounds abil-
ty to inhibit the AHR dependent transcription [86]. Resveratrol
as been shown to be a competitive antagonist of dioxin (TCDD)
long with numerous other ligands of AHR and has been demon-
trated to be involved with the extracellular translocation of the
eceptor through subsequent binding with the dioxin-response
lement. The research group was able to observe that resvera-
rol was a competitive antagonist of AHR and in this particular
a
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tudy competed with TCDD for the AHR binding and was also
esponsible for blocking the CYP1A1 and Il-1 expression at
icromolar levels of concentration [86]. Recent studies indi-
ated that the expression of ER  was independent to the ability
f resveratrol to inhibit AHR dependent transcription and that
etabolites of phytochemicals might contribute toward resver-
trol induced inhibition of AHR mediated activities along with
he mediation of certain biological and anti-neoplastic properties
f the phytochemical compounds [87].
.7.  Human  clinical  trials
Based on the well documented beneficial properties attributed
o resveratrol treatment, human clinical trials are the logical steps
o further explore the benefits and limitations associated with
dministering resveratrol at controlled dosages.
A phase-1 dose escalation resveratrol pharmacokinetic study
as conducted in healthy volunteers [49]. The study of oral
esveratrol included single doses of 0.5, 1, 2.5 or 5 g and was
onducted on 10 healthy individuals. Resveratrol was admin-
stered in the form of immediate-release caplets containing a
osage of 500 mg. The peak levels of resveratrol at the highest
ose were 559 ± 384 ng/mL which occurred 1.5 h after dosage.
t was found that the peak levels of two mono-glucuronides
nd resveratrol-3-sulfate were 3 to 8 fold higher. Resveratrol-
-sulfate and resveratrol monoglucuronides were up to 23 times
reater as compared to resveratrol. The plasma half-lives of the
hree resveratrol metabolite conjugates were 3.2–11.5 h for the
ulfate metabolites and 2.9–10.6 h for the glucuronides and were
imilar to the half-life of parent resveratrol which was 2.9–8.9 h.
 rapid urinary excretion of resveratrol was also observed, with
7 percent of all the urinary agent derived species excreted
ithin 4 h after the lowest dose was administered. Based on
he pharmokinetics study, even on ingesting resveratrol equiva-
ent to the amount found in several hundred red wine bottles, the
oncentrations will still fall between 0.3 and 2.4 mol/L, well
elow the 5 mol/L required to show anti-cancer properties [49].
A similar study in a Spanish population was conducted by the
uropean Prospective Investigation into Cancer and Nutrition
EPIC) [88] in 2007 to assess the concentrations of resveratrol
nd its derivatives in foods and to estimate the principal dietary
ources of these compounds in the Spanish adult population. A
ood composition database (FCDB) of resveratrol and piceids in
panish food was compiled. 40,685 subjects aged between 35
nd 64 years old were included in the study from both the north-
rn and southern regions of Spain with their food intake assessed
hrough a series of personal interviews employing a computer-
zed version of a validated diet history method. Following the
nterview process, a FCD with 160 items were compiled. In order
o assess the resveratrol and piceid intake with respect to various
ttributes such as age, region, education level, etc., estimations
f the portions of consumers and median resveratrol and piceid
ntake was calculated using linear regression analysis. The aver-
ge intake of resveratrol and piceid was found to be 933 g/days
ith a median of 100 g/days. A total of 13,175 participants,
hich included 39% men and 20% women, had a total resvera-
rol intake of 0 g/days. Trans-Piceid contributed 53.7% of total
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esveratrol intake, trans-resveratrol 20.8%, cis-piceid 19.3% and
is-resveratrol 6.2%. The resveratrol and piceid consumption
as lower in quantity and percentage amongst women than in
en. It was found that the most important source of resveratrol
nd piceid was wines with 98.4% followed by grape and grape
uices with 1.6%. Peanuts, pistachios and berries contributed to
ess than 0.01%. They were able to conclude that trans-piceid is
 common component of the Mediterranean diet.
From a double blind, placebo controlled study investigating
our increasing doses of oral trans-resveratrol, bioavailability
f resveratrol is found to be greatest when administered in the
orning [89]. The groups were studied in ascending order of
oses with the trans-resveratrol being administered orally in the
orm of capsules in varying concentrations of 25 mg/placebo in
roup 1, 50 mg/placebo in group 2, 100 mg/placebo in group 3
nd 150 mg/placebo in group 4 and were given at 4 h intervals,
 times a day for 13 doses. The peak plasma concentrations
f trans-resveratrol was reached at 0.8–1.5 h post dose and the
ean apparent terminal half-life ranged from 1 to 3 h follow-
ng trans-resveratrol single-dose and from 2 to 5 h following
epeated dosing. After the 13th dose of trans-resveratrol 25,
0, 100 and 150 mg, the mean peak concentration of plasma
Cmax) was 3.89, 7.39, 23.1 and 63.8 ng/mL and the mean
UC (area under the plasma concentration curve) was 3.1, 11.2,
3.0 and 78.9 ng/(h mL). The trans-resveratrol pharmacokine-
ics showed circadian variation. A total of 18 treatment-emergent
dverse effects (AE) were reported. No case of related AE with
lacebo was reported. The adverse effects were mild in sever-
ty and similar amongst the groups. They concluded that even
hough the repeated dose administration was well tolerated only
 relatively low plasma concentration of trans-resveratrol was
roduced despite of the high doses and short dosing interval.
.8. Summary
Vast research has been conducted analyzing the anti-cancer
otential of resveratrol toward the treatment of breast cancer.
ven with a limitation in terms of a lower bioavailability, studies
re exploring different avenues to bypass this. Clear evidence
xists documenting the anti-proliferative and apoptosis activities
ssociated with resveratrol treatment as well as research data
n cell signaling pathways and metabolite that are specifically
ffected.
. Ursolic  acid
Ursolic acid was first reported to be present in cranberries
90,91] as well as in cranberry press cakes and was not given
uch importance due to the assumption that it was a waste prod-
ct associated with cranberry juice production. Relatively little
nformation regarding the phytochemical is currently known
ue to a lack of scientific research data on the compound’s
ral bioavailability. However, over the years numerous in  vitro
nd in  vivo  researches have been conducted with regards to the
otential health benefits of this particular phytochemical and
mong the reported findings are ursolic acid’s anti-cancer and
nti-inflammatory activities [92–94].
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The compound has recently been identified to be present in
pple peels [95] as well as high blue blueberries [96] and is typi-
ally present in the fruit’s wax layer. Hence, processing methods
sed and the relative presence of fruit peel, stands to have an
ffect on the amount of ursolic acid present [91]. The impor-
ance is further substantiated in a recent research report which
inks the ability of apple peels to lower obesity and burn calories
97]. In light of these research findings, the health benefits asso-
iated with the consumption of apples and other fruits that are
imilar, which can be attributed to the presence of ursolic acid.
.1. Structure  and  chemistry
Ursolic acid is a pentacyclic triterpenoid compound that
xists either in its free acidic form or as aglycones for the
aponins. Terpenoid compounds are present in most plant
pecies and serves as a primary metabolite taking part in
rocesses such as respiration, development and growth and pho-
osynthesis [98]. Certain terpenoid compounds also function as
econdary metabolites to protect the plants against pathogens
nd herbivores [99,100]. The compound has a very low water
olubility which in turn affects their bioavailability [101].
Terpenoid compounds in plants are synthesized through
wo different pathways, the mevalonic (MVA) acid and the
ethylerythritol 4-phosphate (MEP). The biosynthesis of a
ajority of the terpenoid compounds displays a common route
n the synthesis pathway from isopentenyl diphosphate (IPP) to
imethyl-allyl-diphosphate (DMAPP), the essential precursors
or the formation of ursolic acid [102–105].
.2. Sources
Ursolic acids are tri-terpenoid compounds in medicinal herbs,
ood as well as certain plants such as apples, cranberries, prunes,
avender and oregano. They are mainly found along with its
somer oleanolic acid [106]. Apple peels have been shown to
ontain high amounts of ursolic acid [95,107]. They have also
een identified in numerous plant species [99,100,108,109].
.3. Uses
Ursolic acid mainly exists in the form of free acids or agly-
ones for certain triterpenoid saponins. Initially ursolic acid was
onsidered to be a biologically inactive terpenoid compound
106], but due to its low toxicity and pharmacological effects
92] along with various biological functionalities [110], ursolic
cid is being studied to further explore its beneficial properties
111–114].
Due to the relatively low level of toxicity [115], ursolic acid
s generally used in medicine formulations that can be applied
oth orally and topically. In terms of acute toxicity, the LD50
alue resulting from an intra-peritoneal administration in mice
s 637 mg/kg and from oral administration is 8330 mg/kg [116].
rsolic acid has recently been used as a radio-sensitizer, where
n in  vitro  analysis showed its ability to bolster the ionization
adiation induced apoptosis of DU145, CT26 and B16F10 breast
ancer cell lines [117]. A similar radio-sensitizing effect was also
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bserved in  vivo  where ursolic acid administration in conjunc-
ion with ionizing radiation, inhibited the formation of tumor in
ice implanted with the B16F10 melanoma cancer cells [117].
The health benefits of ursolic acid include anti-inflammatory
ctivity [118,119], anti-cancer activity [120–125], and anti-
yper lipidemic activity [126].
.4.  In  vitro  proliferation  and  apoptosis  studies
Pomegranate extract has been shown to inhibit the prolif-
ration of various cancer cells [127] and an HPLC analysis
eveals that it contains approximately 70% total phenolic com-
ounds, a composition that is similar to the components found
n pomegranate juice [128]. One of the phenolic components
resent in a pomegranate extracts is ursolic acid. Pomegranate
xtract inhibited the proliferation of MMTV-Wnt-1 mouse mam-
ary cancer stem cells in a time and concentration dependent
anner by initiating a cell cycle arrest in the G0/G1 phase
129]. A similar study observing the antiproliferative activity of
wo herbal extract mixtures on human breast cancer cell lines,
DA-MB-453 and MDA-MB-361 [130]. The two herbal extract
ixtures act as a good source of ursolic acid or rosmarinic
cid. Ursolic acid has been isolated from apple peel extracts
sing a bioactivity-guided fractionation process [95] and shows
ignificant anti-proliferative activity when treated with MCF-
 breast cancer cells. Similar reports have been observed on
reating MDA-MB-231 cells with ursolic acid which results in
he induction of apoptosis along with the suppression of cancer
ell proliferation [131]. The anti-proliferative activity associated
ith ursolic acid treatment was dose-dependent with an IC50
alue of approximately 40 mol/L at a 24 and 48 h time period
n comparison with the control. Morphological changes of the
ancer cells in terms of shape, size and density were also detected
ollowing treatment. On treating the MDA-MB-231 cells with a
0 mol/L concentration of ursolic acid for a 24 and 48 h period,
 time-dependent increase in the G1 apoptotic fraction was seen
ith an increase from 3.58% to 10.51% in 24 h and 5.19% to
3.09% in 48 h, indicating an induction of cancer cell apoptosis
131]. A concentration dependent inhibition of cell proliferation
nd the induction of apoptosis were also observed when MCF-7
reast cancer cells were treated with ursolic acid [132]. After
 24 h time period following ursolic acid treatment, the IC50 of
rsolic acid was found to be approximately 22.6 ±  3.0 mol/L,
ith a concentration of 50 mol/L found to arrest the cells in
he G0–G1phase of the cell cycle.
.5. In  vivo  studies
Ursolic acid is one of the active phytochemical compounds
resent in Rosemary extract. Rosemary extract when admin-
stered to rats with DMBA (7,1-dimethylbenz[a]anthracene)
nduced mammary tumorigenesis resulted in a decrease in the
ncidence of tumor formation in comparison to the control treat-ent [133]. The study observed a decrease in DMBA binding
o the mammary epithelial cell DNA by approximately 42%
s well as a decrease in the DMBA derived adduct binding
o deoxyguanosine (dGuo). A 51% inhibition of dGuo adduct
d
r
b
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ormation was also seen. A similar study to investigate the anti-
umor effects of ursolic acid on post-menopausal breast cancer
esulted in a decrease in tumor proliferation being observed
134]. Ursolic acid caused a dose-dependent opposing effect
s 0.10% ursolic acid was seen to significantly decrease final
umor growth compared to ursorlic acid treatments at 0.25%
ith higher concentrations observed to induce tumor growth.
rsolic acid at 0.10% induced the maximum tumor inhibition
f 40% as well as decrease cyclin D1 levels while both the con-
entrations, 0.10% and 0.25%, decreased the phosphorylation of
kt, MAPK as well as S6 a downstream effector of Akt/mTOR.
.6. Molecular  target  and  signal  pathway  studies
Ursolic acid treatments of MCF-7 breast cancer cells induced
poptosis through internal mitochondrial pathways [135]. This
nding is further substantiated when on treating MDA-MB-231
ells with ursolic acid an induction of mitochondrial mediated
ancer cell apoptosis was observed [131]. Ursolic acid was found
o release cytochrome C from the mitochondria to the cytosol,
o up-regulate the Bax protein as well as a down-regulate Bcl-2.
his was in conjunction with the cleavage of caspase-9 along
ith a decrease in the mitochondrial membrane potential [131].
Treatment with ursolic acid caused an increase in nuclear
ranslocation of GR as well as the down regulation of Bcl-2
ausing a release of cytochrome C. This was subsequently fol-
owed by an activation of caspase-9 and caspase-3, proteases
hat are involved with apoptosis [136]. Poly ADP-ribose poly-
erase (PARP) is cleaved by capase-9 following its activation.
ven though studies indicated that ursolic acid induced the bind-
ng of AP-1 to its target DNA elements [137,138], however,
rsolic acid was seen to not induce any trans-repression or trans-
ctivation of AP-1 activity which serves to suggest that ursolic
cid responds through a mechanism that does not involve AP-1
ignaling activity. A recent study indicates that MCF-7 apoptosis
y ursolic acid was mediated through the inhibition of Forkhead
ox protein M1 (FoxM1), a protein responsible for cell cycle
rogression, as well as the inactivation of CyclinD1/CDK4, the
ownstream targets of FoxM1 [139]. The FoxM1 transcription
actor is known to regulate target genes that are involved with
he initiation of mitosis and as such is over expressed in most
umors. Ursolic acid is also found to up-regulate the expression
f the p53 protein expression when treated with MCF-7 cells
roviding a possible link to the induction of apoptosis following
reatment [132].
The migration and invasive properties of the breast cancer
ell line MDAMB231 is inhibited on treatment with ursolic acid
140]. Ursolic acid suppressed the MDAMB231 cell growth
t concentrations of 25 or 50 mol/L and viability decreases
n a dose- and time-dependent manner. At concentrations ran-
ing from 0 to 50 mol/L colony formations were suppressed
nd at 10 mol/L cell motility was inhibited. Concentrations
bove 2.5 mol/L decreased cell migration and invasion in a
ose- and time-dependent manner. Ursolic acid treatment also
educed MMP-7 and plasminogen activator (u-PA) activities
y 35% and 42%, respectively, at a 10 mol/L concentration
hich corresponded to an increase in TIMP-2 (tissue inhibitor
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f MMP) and PAI-1 (plasminogen activator inhibitor) protein.
his reduction in MMP activity was linked to the inactivation
f Akt, mTOR and JNK by ursolic acid in a time-dependent
anner with the inactivation being responsible for the inhi-
ition of cell invasion and migration. Ursolic acid treatment
lso reduced NF-кB, c-Jun and c-Fos protein levels in the
ucleus and also inhibits the metastasis and angiogenesis related
ignaling cascades RhoA (Rho-like GTPases), Grb2, Ras and
ascular endothelial growth factor (VEGF). NF-кB activity was
uppressed through the inhibition of IB  kinase and p65 phos-
horylation [141]. Ursolic acid prevented the DNA binding
f the NF-кB that consists of p50 and p65 along with the
nhibition of NF-кB reporter gene expression through tumor
ecrosis factor receptor (TNFR), tumor necrosis factor recep-
or type 1-associated death domain protein (TRADD), tumor
ecrosis factor receptor associated factor-2 (TRAF2), necrosis
actor kappa-B inducing kinase (NIK), IB kinase (IKK) as well
s p65.
COX-2 is an enzyme that is typically over-expressed in var-
ous forms of cancer. The enzyme acts on arachidonic acid
nd converts it into Prostaglandin H2 (PGH2). PGH2 is then
cted on by Prostaglandin E2 synthase (PGE2) converting it
nto Prostaglandin E2 (PGE2), a compound that is known to
ncrease the rate of cancer progression. Ursolic acid inhibited
he COX-2 transcription in human mammary epithelial cells
reated with phorbol 12-myristate 13-acetate (PAM), a tumor
romoter [142,143]. Ursolic acid suppressed COX-2 activity
y inhibiting the PKC signaling pathway through a blockage
f the translocation of the PKC signaling from the cytosol to
he membrane as well as inhibiting the activation of ERK1/2,
NK and p38 MAPK [144]. The TNF-related apoptosis induc-
ng ligand (TRAIL) is a protein that induces the process of
poptosis. The protein typically binds to the TNFR, DR4 and
R5 in order to initiate the process of apoptosis. Even though a
ajority of the cancer cells are resistant to TRAIL induced apo-
tosis [145], treatment with ursolic acid was shown to sensitize
he cancer cells to the TRAIL induced process [146]. Urso-
ic acid treatment was revealed to up-regulate the expression
f death receptors (DR) through JNK mediation, activate the
OS and to down-regulate the expression of survival proteins
nd DCR2, a receptor that contains a truncated death domain
146].
.7. Summary
The beneficial effects of ursolic acid have traditionally
een observed through the use of herbal medicine due to
ts presence in many plant species. The identification of the
ompound in apples and fruits followed by reported data
n its potential anti-cancer properties served to pave way
or future scientific research exploring its health beneficial
otential. Numerous researchers have documented the anti-
roliferative and apoptosis activity attributed to treating breast
ancer cells with ursolic acid. It has also been documented
o affect cellular signaling pathways as well as individual
etabolites.d Human Wellness 1 (2012) 1–13 9
.  Conclusion
There is a growing emphasis placed by consumers on eat-
ng healthy as a means toward preventing the onset of disease.
n light of that very change, resveratrol and ursolic acid are at
he forefront in terms of exposure and potential health benefits.
he discovery of resveratrol as a component in red wine and its
otential link to providing cardio-vascular protection has opened
oors to explore further its health beneficial capabilities. Various
esearches report the anti-tumor, anti-inflammatory and apopto-
is properties of resveratrol along with the signal transduction
athways that are affected by the compound. With clinical trials
eporting the benefits of resveratrol in terms of anti-cancer prop-
rties, the commercial application of administering resveratrol
as been suggested. With the bio-availability still being a draw-
ack, further research needs to be made in this avenue in terms
f a potential delivery system or encapsulation system which
an increase the bioavailability of the compound.
Ursolic acid has been used in traditional medicine for a long
ime and is commonly attributed to be one of the underlying
actors responsible for bestowing the health beneficial effects.
ollowing the recent discovery of the ability of ursolic acid to
educe obesity and burn calories, the compound in currently
n the lime light. The anti-cancer and anti-inflammatory activ-
ties have been documented by various research groups across
ifferent cell lines. With more research currently being done
n the oral bioavailability of the compound, based on the future
esearch findings, a potential avenue to explore will be to conduct
linical trials.
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